BIO Asia–Taiwan 2021 亞洲生技大會

BIO Asia–Taiwan 2021 亞洲生技大會

講師

Tansoar Biotech, Ltd - SPARK

 

Universal antibody lock to selectivity and safety/Tansoar Biotech, Ltd - SPARK

Company Info

Name /Universal antibody lock to selectivity and safety/Tansoar Biotech, Ltd - SPARK

Address /12F, First Teaching Building, 100, Shih-Chuan 1st Road, Kaohsiung, 80708, Taiwan

Website /https://www.tansoar.com.tw

Expecting startup year /2020

No. of team members /4

Presenter

Name /Yun-Chi Lu

Title /CEO/Ph.D

Email /mogulyc@gmail.com

Telephone /(Work) 07-3111577

Fax /

Mobile /0916522487

Company Type

Biotechnology

About the Company

PrecismAb Biotech, Co., Ltd. will be established this Autumn, led by Chair professor Tian-Lu Cheng, Kaohsiung Medical University. We are committed to reducing the side effects of monoclonal antibody drugs and providing safer and more effective therapy. Our core technology, “universal antibody lock”, can improve the disease selectivity of antibody and enhance the safety of antibody treatment. Now we are looking for any co-development and licensing opportunity of antibody drug with pharmaceutical companies. Moreover, we will get technology investments from KMU this year and raise US$1.5 million in seed funding to achieve four co-developing antibodies and the one license-out of our antibody drug.

Brief Description of main products or services

We used the antibody hinge domain as a spatial hindrance-based “antibody lock” to cover the antibody's antigen-binding site to generate pro-antibody. After the antibody lock is removed by expression of protease in the disease region, the cleaved pro-antibody is expected to be specifically activated and neutralize the target antigen to inhibit the disease progression. The universal antibody lock based on spatial-hindrance can effectively mask the antigen-binding of antibodies, efficiently restore the biological activity by disease-associated proteases and selectively react at the disease site to prevent severe on-target toxicities caused by systemic administration of antibody drugs. We provide 2 kinds of services: (1) The optimized pro-Ab (Bio-betters): We’ve targeted the 10 popular antibody drugs (FDA-approved) that with serious side effects, and transform them into optimized pro-Abs. These 10 clones of lock-antibodies have finished proof of concept assays and ready to further co-development or licensed out. (2) Customized research service of a New Pro-antibody: If you have any antibody candidates with a safety concern, we can provide a comprehensive customized service for your antibody included: drug design and functional verification and CMC production and pre-clinical studies. We can finish the drug design and in vitro function test in 3 months.

Contact Person

Name /Yun-Chi Lu

Email /mogulyc@gmail.com

Phone /(Work) 07-3111577